FDG-PET/CT Study
Protocol Title:
ACRIN 6678: FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-Small Cell Lung Carcinoma (A Multicenter Clinical Trial)
Working Title:
ACRIN 6678: FDG PET/CT to Evaluate Treatment Response in Non-Small Cell Lung Cancer Summary:
The purpose of this clinical trial is to demonstrate that quantitative changes in FDG uptake during chemotherapy provides an early indication of the effectiveness of therapy in patients with advanced non-small cell lung carcinoma (NSCLC). Enrollment Status:
Anticipated start: 6/30/2007 Principal Investigator:
Peter J. Julien, MDAlan D. Waxman, MD
IRB Approval Number:
11546 Medical Specialty Area:
PET/CT Imaging, Oncology Condition/Disease:
Non-Small Cell Lung Carcinoma IRB Approval Expiration Date:
04/30/2008 Contact Information for patients wishing more information:
Name: Rene Siegel, Program Coordinator, Imaging Research Phone: (310) 423-3398
E-mail: SiegelR@cshs.org
